HRT Prescriptions by State: 5 Coverage Laws (2026 Guide)

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:September 2, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: September 2, 2026 · Last verified: September 2, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before you choose an HRT route by state

Separate state access, insurance coverage, medication fit, and when online care is not the right starting point.

Use Find My HRT Path

Answer capsule: HRT prescriptions by state are legal nationwide for menopause care, but the route changes. Clinician licensing follows where you are during the visit, provider footprints differ, and five states have enacted menopause-coverage mandates. Four have active provisions now; Virginia applies to policies beginning January 1, 2027. Washington adds refill protection, not a treatment-coverage mandate.

Best for you if: you got a “not available in your state yet” message, your clinician said no and you are trying to separate one clinician’s decision from state law, or you want to know what your insurance may owe before you pay cash.

Not for you if: you are looking for state laws on gender-affirming hormone therapy. That is a different legal landscape with different rules, and this page does not cover it.

Answer capsule: Three separate state-level questions decide what happens next: whether a clinician can treat you where you are physically located, whether the provider’s visit model satisfies that jurisdiction’s rules, and whether your health plan must cover menopause care. Solving only one of those questions can still leave you blocked at checkout.

What changes	Why it matters	Where to resolve it
Clinician and provider footprint	Decides whether that company can treat you while you are physically in the state	Provider and state matrix
Visit and prescribing pathway	Decides whether messaging alone, a live appointment, an exam, or another step is needed	Questionnaire and live-visit rules
Insurance law and plan type	Decides whether a state mandate can help—and whether ERISA keeps your employer plan outside it	Coverage laws

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified for this page
On September 2, 2026, we checked each provider footprint and price against the provider’s own live pages. We hand-counted Winona’s public directory at 37 states plus Puerto Rico, recorded Elektra’s 16-state clinical footprint, and separated “all 50 states” claims from explicit Washington, D.C. and Puerto Rico coverage.
We also traced the five enacted menopause-coverage laws to official state sources, read Washington’s refill statute separately, checked the current federal telehealth location rule, confirmed the December 31, 2026 controlled-substance telemedicine date, and recalculated recurring prices that are billed every 28 days.
What we did not do: enroll with every provider, run checkout in every jurisdiction, call every health plan, or make a legal determination for an individual reader. “Provider-published” verifies what the company says publicly; it does not guarantee that your exact plan, clinician, medication, or appointment slot will clear intake.

Are HRT prescriptions by state legal everywhere in the U.S.?

Answer capsule: Yes for menopause care: our September 2026 review found no state law banning FDA-approved menopausal hormone therapy for menopause. Estradiol products, oral micronized progesterone, and local vaginal estrogen are prescription medicines rather than controlled substances. State differences affect the prescriber, visit pathway, pharmacy, insurer, and product—not whether menopause treatment itself is legal.

Let’s clear the fear out of the way first, because it is why a lot of women land here.

An estrogen patch is not a controlled substance. Neither is oral micronized progesterone or vaginal estrogen. The prescription still has to come from a clinician who can lawfully treat you and who decides the medication is appropriate, but a provider’s “not available” screen is not a state ban on menopause care.

In February 2026, the FDA approved labeling changes for six specific menopausal hormone therapy products, removing certain risk statements from their boxed warnings. That did not rewrite every estrogen or progesterone label. The exact product still matters, and the FDA’s action is not permission to treat all formulations as interchangeable.

There is one separate lane: testosterone. No testosterone product is FDA-approved specifically for women in the United States, any prescription for a woman is off-label, and testosterone is a Schedule III controlled substance. Never use a company’s estrogen footprint to guess at its testosterone footprint.

Why does “available in all 50 states” still fail at checkout?

Answer capsule: A nationwide claim answers only the first access question. It does not prove the company offers your medication in that state, accepts your insurance, has an available clinician, can use its preferred pharmacy there, or can prescribe a controlled substance. Access is a five-layer chain, and a single failed layer can stop the path.

Access layer	The real question	What can stop you
1. Physical location	Can this clinician legally treat a patient physically located here?	The clinician is not licensed or otherwise authorized in that jurisdiction
2. Visit model	Does the intake and clinical interaction satisfy the applicable standard of care?	A questionnaire-only workflow is not enough for that situation or profession
3. Medication lane	Is the request noncontrolled, controlled, FDA-approved, or compounded?	Testosterone rules or a pharmacy-licensure limit
4. Provider operations	Does the company actually offer that product and have capacity there?	No clinician capacity, appointment inventory, or state formulary
5. Payment and fulfillment	Will the health plan and pharmacy complete the path?	Out-of-network care, an uncovered drug, prior authorization, or pharmacy restrictions

For telehealth, the state that usually matters is where you are physically located during the appointment. The federal telehealth licensure guide tells providers to verify patient location and meet the licensure or authorization rules of that location. Your mailing address does not override where you are sitting during the visit.

Two gaps matter before you trust a nationwide badge:

“All 50 states” does not automatically include Washington, D.C. or Puerto Rico. Evernow explicitly publishes all 50 states plus D.C. Winona explicitly lists Puerto Rico. Do not silently add either jurisdiction to another company’s “50 states” statement.
“Not listed” does not mean “not allowed.” It means the company does not publish service there on the page we checked. It is not a legal conclusion about HRT or every other provider.

Which HRT providers serve your state?

Answer capsule: Four services in this audit—Midi Health, Gennev, Wisp, and Evernow—publish all-50-state menopause access, although only Evernow explicitly adds Washington, D.C. Winona publishes 37 states plus Puerto Rico, while Elektra publishes 16 states. Price is only comparable after separating visit fees, membership fees, medication, labs, insurance, and refill timing.

Provider	Provider-published footprint	Current care price	Payment and fulfillment model	The catch you should know
Midi Health	All 50 states	$250 initial and $150 continued-care visit when self-pay	Bills many commercial plans; no membership; prescriptions generally run through your pharmacy benefit	Cannot treat Medicaid or Medi-Cal patients, even self-pay. Medicare beneficiaries can self-pay but cannot submit Midi claims
Gennev	All 50 states	$250 initial doctor visit; $199 doctor follow-up when self-pay	Insurance eligibility is plan-specific; medication is separate	The draft’s $199 initial price and three-carrier limit were outdated
Wisp	All 50 states	$99 menopause consult	Consult, follow-up access, and a prescription when appropriate; medication is paid separately at the local pharmacy	The public page does not support the draft’s claim that Wisp “orders no labs at all”
Evernow	All 50 states plus Washington, D.C.	$49 month-to-month, $129 for three months, or $420 for twelve months; optional self-pay video visit $150	Membership and medication are separate; insurance support varies	Medicare and Medicaid are not supported on the current FAQ
Winona	37 states plus Puerto Rico	From $39 for progesterone capsules, $89 for combined cream, and $149 for estradiol patches	Cash program; products ship through its pharmacy pathway; 30-day supplies process every 28 days	Ages 35–59; no phone or video visit; only a 24-hour processing window for a full refund
Sesame	No complete current public menopause state directory found	From $59 per month	Video care and messaging; prescription goes to a local pharmacy; medication is separate; listed basic labs are included when ordered, subject to state exceptions	Sesame does not permit online controlled-substance prescribing, so this is not a testosterone route
Elektra Health	16 states	$249 initial; $149 follow-up when self-pay	Prescribes FDA-approved medication only; accepts selected commercial, Medicare, and Medicaid plans in specified states	Insurance acceptance is not nationwide, and its clinical footprint is much smaller than the all-50-state services

The damaging admission about our widest insurance recommendation: Midi is not your answer if you have Medicaid or Medi-Cal, and it is not a Medicare-billing solution. That is a hard stop, not a footnote. If you need public-plan participation, Elektra’s plan-specific route or an in-person clinician is the more honest place to start.

The Winona number most price pages miss: a $149 starting price processed every 28 days annualizes to about $1,943 per 365 days, not $1,788. If a clinician prescribes both the $149 patch and $39 progesterone capsules at those starting prices, the recurring annualized amount is about $2,451. Those are arithmetic scenarios, not guaranteed quotes; dose, product, tax, and treatment plan can change the total.

Why Hers is not mapped here: Hers did not publish a complete current state directory we could verify. We also are not linking it commercially in this guide while the Federal Trade Commission’s July 2026 complaint remains pending. The complaint alleges deceptive privacy, billing, and cancellation practices; those allegations have not been finally adjudicated.

The state-by-state provider and coverage matrix

Answer capsule: This matrix combines three things that are normally scattered across separate sites: Winona’s 37-state-plus-Puerto-Rico directory, Elektra’s 16-state clinical footprint, and enacted menopause insurance laws. Midi, Gennev, Wisp, and Evernow publish all 50 states, so their names are not repeated in every row. “Not listed” is a provider statement, not a legal conclusion.

Jurisdiction	Winona public directory	Elektra clinical care	Enacted menopause coverage or refill law
Alabama	Not listed	Not listed	—
Alaska	Not listed	Not listed	—
Arizona	Listed	Listed	—
Arkansas	Not listed	Not listed	—
California	Listed	Not listed	—
Colorado	Listed	Not listed	—
Connecticut	Listed	Listed	—
Delaware	Listed	Not listed	—
Florida	Listed	Listed	—
Georgia	Listed	Listed	—
Hawaii	Listed	Not listed	—
Idaho	Listed	Not listed	—
Illinois	Listed	Listed	Coverage mandate active Jan. 1, 2026
Indiana	Listed	Not listed	—
Iowa	Listed	Listed	—
Kansas	Not listed	Not listed	—
Kentucky	Listed	Not listed	—
Louisiana	Not listed	Not listed	Coverage mandate active Aug. 1, 2024
Maine	Listed	Not listed	—
Maryland	Listed	Not listed	—
Massachusetts	Listed	Listed	—
Michigan	Listed	Not listed	—
Minnesota	Listed	Not listed	—
Mississippi	Not listed	Not listed	—
Missouri	Listed	Listed	—
Montana	Listed	Not listed	—
Nebraska	Listed	Listed	—
Nevada	Listed	Not listed	—
New Hampshire	Listed	Not listed	—
New Jersey	Listed	Listed	Most provisions active Apr. 9, 2026; individual market Jan. 1, 2027
New Mexico	Not listed	Not listed	—
New York	Listed	Listed	—
North Carolina	Listed	Not listed	—
North Dakota	Not listed	Not listed	—
Ohio	Listed	Listed	—
Oklahoma	Listed	Listed	—
Oregon	Listed	Not listed	Coverage mandate active Jan. 1, 2026
Pennsylvania	Listed	Listed	—
Rhode Island	Not listed	Not listed	—
South Carolina	Listed	Not listed	—
South Dakota	Not listed	Not listed	—
Tennessee	Listed	Listed	—
Texas	Listed	Listed	—
Utah	Not listed	Not listed	—
Vermont	Not listed	Not listed	—
Virginia	Listed	Not listed	Coverage applies to policies beginning Jan. 1, 2027
Washington	Listed	Not listed	12-month refill protection active Jan. 1, 2026; not a treatment-coverage mandate
West Virginia	Not listed	Not listed	—
Wisconsin	Listed	Not listed	—
Wyoming	Listed	Not listed	—
Washington, D.C.	Not listed	Not listed	—
Puerto Rico	Listed	Not listed	—

How to read the dash: we did not identify an enacted menopause-specific coverage mandate for that jurisdiction in the September 2, 2026 review. A dash does not mean your plan excludes HRT, that your state Medicaid program excludes it, or that no proposed bill exists.

The D.C. and Puerto Rico gap: Evernow explicitly includes Washington, D.C. Winona explicitly includes Puerto Rico. For every other provider, a “50 states” statement should not be stretched beyond the words the company published.

Decision Resolution Point — insured and not on Medicaid: Midi publishes all-50-state care and bills many commercial plans. If that fits your situation, check whether Midi is in-network where you will be during the visit (sponsored link).

Why isn’t my provider available in my state?

Answer capsule: State availability is usually a company-level decision built from clinician licenses, the required clinical interaction, pharmacy permissions, malpractice rules, appointment capacity, and medication type. A questionnaire rule can explain part of a footprint, but it cannot prove why a company serves or skips a state. The right question is how your prescription will actually be authorized.

“Asynchronous” care means the patient submits information and the clinician reviews it later rather than meeting in real time. Winona’s public state page says it does not require a video call and instead starts with an onboarding questionnaire.

Some state laws draw a line around a relationship established only through a questionnaire. Arkansas Code §17-80-403, for example, says a professional relationship does not include one created solely through an internet questionnaire, email, patient-generated history, text, fax, or combinations of those methods. That does not make telehealth illegal. It means the complete clinical workflow has to satisfy the state’s rule and the applicable standard of care.

Now here is where we argue against ourselves

A restrictive-sounding questionnaire rule does not let us reverse-engineer a provider’s map. Winona serves Colorado and Oregon even though public policies in those states have also been read as rejecting treatment based solely on an online questionnaire. A clinician review, two-way messaging, professional scope, and ongoing follow-up can change the analysis. So can pharmacy licensing and business capacity.

We are not accusing any company of unlawful prescribing. We are showing why one sentence—“available in your state”—does not tell you what happens between intake and prescription.

Ask this before you pay:

“Will my first prescription come from a questionnaire review, or do I need a live appointment? Is the clinician licensed where I will physically be during the visit, and what happens if the clinician decides more evaluation is needed?”

A company that can answer that cleanly is giving you something more useful than a “nationwide” badge.

Which states require insurance to cover menopause treatment?

Answer capsule: Five states have enacted true menopause-treatment coverage mandates: Illinois, Louisiana, New Jersey, Oregon, and Virginia. Illinois, Louisiana, Oregon, and most New Jersey provisions are already active; Virginia applies to policies beginning January 1, 2027. Washington is separate: it protects longer refills when a plan already covers prescription hormone therapy.

State	Status on September 2, 2026	What the enacted law does	The limit that matters	Primary source
Illinois	Active January 1, 2026	Requires covered, medically necessary hormonal and nonhormonal menopause care under affected state-regulated plans, including FDA-approved modalities	Network, medical-necessity, cost-sharing, and plan terms can still apply	Illinois Public Act 103-0703
Louisiana	Active August 1, 2024	Requires coverage of medically necessary perimenopause and menopause care; includes Medicaid provisions	The no-prior-authorization and no-step-therapy rule for HRT is written for affected private plans; plan scope still matters	Louisiana Act 784
New Jersey	Most regulated-plan provisions active April 9, 2026; individual-market applicability begins January 1, 2027	Requires broad medically necessary perimenopause and menopause benefits across listed plan types and includes NJ FamilyCare	The effective date differs by market; coverage does not erase networks, cost sharing, or clinical review	New Jersey P.L. 2025, c. 200
Oregon	Active January 1, 2026	Requires affected state-regulated plans to cover a range of FDA-approved therapies for perimenopause, menopause, and postmenopause	Self-funded employer plans and federal programs require separate analysis	Oregon Division of Financial Regulation
Virginia	Enacted in 2026; applies to policies, contracts, and plans beginning January 1, 2027	Requires affected plans to cover medically necessary and generally recognized perimenopause and menopause services	It is not a September 2026 current-plan entitlement; the policy date controls	Virginia Code §38.2-3418.23
Washington	Refill protection active January 1, 2026	When a plan already covers prescription hormone therapy, it generally must reimburse an extended refill—up to twelve months for eligible noncontrolled medication	It does not create a duty to cover menopause treatment in the first place; controlled substances and shortage limits are different	Washington RCW 48.43.845

The caveat that decides whether the law is yours

State mandates generally apply to state-regulated insurance. A self-funded employer plan is governed primarily by federal ERISA rules and can sit outside the state mandate. Do not guess from the insurer logo: the same carrier can administer both fully insured and self-funded plans.

Ask HR or the plan administrator:

“Is this plan fully insured or self-funded, and which entity makes the final coverage decision?”

Then ask the insurer for the relevant menopause benefit, formulary rule, prior-authorization criteria, and appeal instructions in writing.

If you are in a mandate state, do not pay cash on autopilot

We are about to tell you not to buy from one of our partners.

A mandate does not mean every visit and prescription will be free. It does mean paying a cash subscription before checking a benefit you may already have is a bad order of operations. Start with a clinician or telehealth service that bills your plan, then run the prescription through your pharmacy benefit.

Use this script:

“Does my fully insured plan fall under the state menopause-care mandate?”
“Is this clinician in-network?”
“Which FDA-approved estrogen, progesterone, vaginal estrogen, and nonhormonal options are on formulary?”
“Is prior authorization required, and what exact criteria apply?”
“If you deny it, send the denial and appeal rights in writing.”

Decision Resolution Point — state mandate or strong commercial coverage: do not start with a cash bundle. Compare online menopause providers that bill insurance first.

Does Medicaid or Medicare cover HRT in my state?

Answer capsule: Public-program coverage has two separate layers: whether the program covers the visit and whether its drug benefit covers the prescription. Louisiana and New Jersey enacted menopause benefits that reach their Medicaid programs, but implementation, formulary, prior authorization, and provider participation still matter. Telehealth company acceptance is often the narrower door than the medication itself.

Now the flaw in the provider we recommend most often for commercially insured readers:

Midi cannot treat Medicaid or Medi-Cal patients, even as self-pay patients. Its public guidance also says it does not bill Medicare or Medicare-related plans. Medicare beneficiaries may use Midi as self-pay but cannot submit the visit for reimbursement.

If you have Medicare or Medicaid, Midi is not your answer. Elektra is worth checking because it lists selected Medicare and Medicaid participation in specific states, but “Elektra accepts Medicaid” is not a nationwide promise. The exact plan, state, and provider network still control. Evernow’s FAQ says Medicare and Medicaid are not supported. Sesame is a self-pay care service rather than an insurance-billing solution.

The clean way to check:

Ask the telehealth company whether it can see beneficiaries, not only whether it “accepts insurance.”
Ask the plan whether the visit is covered and whether the clinician is in-network.
Search the program’s drug formulary for the exact product, route, strength, and quantity.
Ask whether prior authorization, step therapy, or quantity limits apply.
Keep compounded medication in a separate lane; Medicare and Medicaid coverage for compounded drugs is not the same as coverage for FDA-approved products.

A provider can accept your plan for the visit while the pharmacy claim still fails. The reverse can happen too: the drug is covered, but the telehealth visit is not.

What is the cheapest legal way to get HRT in your state?

Answer capsule: For many insured women, the lowest full-year total is an insurance-billed visit plus FDA-approved medication filled through the existing pharmacy benefit. Cash programs can be faster and simpler, but their membership, medication, shipping, labs, and refill cycle must be annualized together. A visit fee and a bundled medication price are not the same kind of number.

Route	Reproducible first-year care-fee scenario	Medication and lab treatment	Who this fits
Midi self-pay	$250 initial + two $150 follow-ups = $550	Medication and ordered labs separate; insurance may lower the visit total	Commercially insured women who want a broad state footprint and local-pharmacy fulfillment
Gennev self-pay	$250 initial + two $199 follow-ups = $648	Medication and labs separate	Women who want a live menopause-focused clinician and can use insurance or self-pay
Wisp	$99 consult	Medication paid separately at a local pharmacy	A straightforward noncontrolled prescription request when its consult model fits
Evernow	$420 prepaid twelve-month membership, or $588 across twelve $49 monthly payments	Medication separate; optional self-pay video visit is $150	Ongoing membership support without assuming insurance
Winona patch	At the posted $149 starting price every 28 days: about $1,943 per 365 days	Medication included in that product price	Cash-pay women ages 35–59 who value an asynchronous path and accept the billing/refund model
Winona patch + progesterone capsules	At posted $149 + $39 starting prices every 28 days: about $2,451 per 365 days	Both products included in the arithmetic scenario	Only when a clinician actually prescribes both products
Sesame	From $59 × 12 = $708	Medication separate; listed basic labs included if ordered, subject to state exceptions	Women who want ongoing self-pay care and local-pharmacy fulfillment
Elektra self-pay	$249 initial + two $149 follow-ups = $547	Medication and nonincluded services separate	Women in its 16-state footprint, especially where an accepted plan applies

These are comparison scenarios, not treatment schedules. A clinician may want more or fewer visits, prescribe a different product, order labs, or change the route. The point is to put unlike price models on one year-long ruler.

The 28-day problem is not cosmetic

“$149 per month” sounds like $1,788 per year. Processing every 28 days produces about 13.04 cycles per 365 days, which annualizes to about $1,943. The program may ship a 30-day supply while processing on a 28-day schedule; the charge interval is what drives the recurring annualized amount.

The outside-pharmacy route needs confirmation before you count it

Winona’s help materials have described a $50 platform fee when a prescription is sent to an outside pharmacy. That may change the math for an FDA-approved product, but it is not a promise that every clinician will write every product that way or that every pharmacy will fill it. Confirm the exact product, fee, and fulfillment route in writing before checkout.

Decision Resolution Point — local pharmacy and no controlled substance: Sesame’s current menopause program starts at $59 per month and sends prescriptions to a local pharmacy when appropriate. Compare Sesame with the other cash-pay options before you commit.

For a deeper breakdown of medication, visit, and laboratory costs, see HRT cost in 2026.

Does the medicine you want change the state answer?

Answer capsule: Yes. FDA-approved finished drugs and compounded preparations travel through different regulatory and pharmacy pathways. A clinician may be licensed in your state while the dispensing pharmacy cannot ship a compounded product there. FDA-approved products have premarket review and standardized labeling; compounded finished drugs do not receive FDA approval or the same premarket review.

Lane	What it means	State-access consequence	What to ask
FDA-approved finished medication	The finished product was reviewed by FDA for its approved use, manufacturing, quality, and labeling	Usually filled through a licensed retail or mail pharmacy; formulary and prior authorization can still block it	“Which exact product, manufacturer, route, and pharmacy will be used?”
Compounded finished medication	A pharmacy prepares an individualized finished drug; the finished product is not FDA-approved	The compounding pharmacy must be able to dispense into the patient’s jurisdiction, creating another access layer	“Why is compounding needed, which pharmacy prepares it, and is that pharmacy licensed to ship here?”

Estradiol patches, gels, oral tablets, vaginal tablets, creams, and rings have FDA-approved options. Oral micronized progesterone also has an FDA-approved option. That does not make every strength, combination, cream, or custom formulation FDA-approved.

Compounding is legal and can solve a real patient-specific need, such as an unavailable dose or an allergy to an ingredient. But a compounded finished drug is not FDA-approved, the FDA does not review its safety, effectiveness, or quality before marketing, and “bioidentical” is not a regulatory approval category.

Winona’s public materials correctly identify its patches and progesterone capsules as FDA-approved products and its custom creams as compounded. Elsewhere, provider marketing may describe “FDA-approved ingredients.” That phrase does not turn the final compounded product into an FDA-approved drug.

A 2023 peer-reviewed study found lower estrogen exposure among users of compounded transdermal estradiol creams than among users of FDA-approved patches or gels, although exposure rose with cream dose. That study does not tell you an individual woman’s outcome. It does give you a concrete reason to ask how dose, route, symptom response, and follow-up will be handled.

If you have a uterus and a clinician recommends systemic estrogen, ask what protects the endometrium. Clinical guidance generally pairs systemic estrogen with adequate progestogen for a woman with an intact uterus; low-dose local vaginal estrogen is a different treatment lane.

Can telehealth prescribe testosterone to women in every state?

Answer capsule: No. Testosterone access is narrower because no product is FDA-approved specifically for women in the United States, prescribing is off-label, and testosterone is a Schedule III controlled substance. Provider policy, clinician judgment, baseline and follow-up monitoring, federal telemedicine rules, and state controlled-substance law all sit on top of ordinary telehealth licensure.

Provider	Published testosterone position	Published jurisdiction or limit	What it means
Midi	Compounded testosterone cream after clinician evaluation and testing; starts at $100 for a 90-day supply	Publishes availability in 25 jurisdictions—24 states plus Washington, D.C.	The broadest clearly published menopause-focused telehealth pathway in this audit
Elektra	Some clinicians may prescribe testosterone	Provider FAQ limits that statement to New York residents	Not a 16-state testosterone promise
Winona	Says it does not offer testosterone	None	Its estrogen/progesterone footprint cannot be used for testosterone
Sesame	Platform does not permit online controlled-substance prescribing	None	Not a testosterone route, even where the menopause program is available

Midi’s 25 published jurisdictions are Arizona, California, Colorado, Delaware, Florida, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, New Jersey, New Mexico, Nevada, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Utah, Virginia, Washington, and Washington, D.C.

The DEA’s current temporary rule allows controlled-substance prescribing through telemedicine without a prior in-person medical evaluation through December 31, 2026, when all other federal and state conditions are met. That extension does not erase the prescription requirement, clinician evaluation, state law, quantity rules, pharmacy rules, or a provider’s own stricter policy.

The practical question is not “Does this company prescribe HRT?” It is:

“Does this clinician prescribe testosterone for women physically located in my state, what indication do they use, what labs and follow-up are required, which pharmacy dispenses it, and what happens if federal telemedicine rules change?”

What happens if you move, travel, or need a refill in another state?

Answer capsule: The visit and the refill are separate events. The clinician generally must be authorized where you are physically located during a telehealth appointment. Pharmacy transfer, dispensing, mailing, and refill rules vary by medication, jurisdiction, prescription status, and pharmacy. Do not assume a valid home-state prescription will transfer automatically—confirm before travel or moving.

For a temporary trip:

Tell the provider where you will physically be for any scheduled visit.
Ask whether the clinician is authorized to treat you there.
Ask your dispensing pharmacy whether it can transfer or fill that exact prescription.
Confirm shipping rules before sending a bundled or compounded medication to a new address.
For testosterone or another controlled substance, ask both the prescriber and the pharmacy; controlled-substance rules are different.

For a permanent move:

Check your provider’s public footprint for the new state.
Request your medication list, current dose, monitoring history, and recent records before changing providers.
Book the new prescriber before canceling the current program.
Identify the next automatic charge and cancellation deadline.
Keep enough time for a clinician review; do not build continuity around a same-day transfer assumption.

The safest sentence here is also the least dramatic: call before you travel, and line up the new prescriber before you cancel.

Are HRT prescription rates published by state?

Answer capsule: We did not find a current public all-payer dataset that reports menopause hormone-therapy prescribing rates for every U.S. state. The major 2025–2026 studies and dashboards we reviewed report national trends, selected health-system populations, or Medicare drug data. A state-colored map can look precise while answering a narrower question than the searcher thinks.

National data still shows a real rebound. Epic Research reported a 72% increase in hormone-therapy prescribing among women ages 50–65 from the second quarter of 2021 through the third quarter of 2025, later updating the increase to 86% through the fourth quarter of 2025. A July 2026 Epic analysis reported outpatient hormone-therapy use rising from 1.7% in January 2017 to 3.6% in April 2026.

Those are not state rates. Medicare Part D publishes geographic drug data, but Part D is a defined older and disabled population; it misses much of the 45–59 age range central to menopause care. Claims databases and health-system datasets can also be geographically broad without being a complete state population.

So when you see a U.S. state map, ask:

Is the denominator all women, women in a health system, insured members, or Medicare beneficiaries?
Does “HRT” mean systemic estrogen, local vaginal estrogen, testosterone, all hormone drugs, or a particular prescription?
Is the map counting prescriptions, unique patients, days supplied, or visits?
Is the year current?
Does the source disclose suppressed or missing states?

We would rather publish a missing-data finding than color 50 states with estimates that look more certain than they are.

When online care is not the right starting point

Answer capsule: Online menopause care can be a useful starting point, but a state-licensed telehealth clinician cannot replace every examination, imaging study, or urgent evaluation. Bleeding after menopause, unresolved abnormal bleeding, a new breast finding, severe or sudden symptoms, or a complex cancer, clotting, stroke, or liver history can require in-person or specialist care first.

We would rather lose the click here than route you into the wrong starting point.

Start with an in-person clinician—or urgent care or emergency care when symptoms demand it—if you have:

Bleeding after menopause or unexplained abnormal bleeding. ACOG recommends prompt evaluation of postmenopausal bleeding. Do not accept a website’s generic reassurance as the workup.
A new breast lump or an abnormal breast study you have not followed up.
Chest pain, trouble breathing, one-sided weakness, sudden severe headache, or signs of a blood clot. Those are not routine telehealth intake questions.
A history that requires records and specialist coordination, including breast or endometrial cancer, prior blood clots or stroke, or significant liver disease.
Symptoms that may not be menopause. Thyroid disease, anemia, pregnancy, medication effects, sleep apnea, and other conditions can overlap.

That is not a reason to give up on menopause treatment. It is a reason to start where someone can examine you, obtain records, and order the right workup.

For a structured symptom record before the appointment, use the perimenopause symptoms checklist.

What should you ask before paying for online HRT?

Answer capsule: Six written questions prevent most expensive surprises: clinician authorization where you will be, visit format, FDA status, pharmacy and fulfillment, full-year cost, and cancellation consequences. The goal is not to interrogate a provider. It is to make the first prescription, first charge, and first refill match the path you thought you were buying.

Copy these into the provider’s chat or intake message:

“Is the prescribing clinician licensed or otherwise authorized where I will physically be during the visit?”
“Will my first prescription require a live appointment, or can your full clinical workflow be completed asynchronously?”
“Is the finished product FDA-approved or compounded? What is the exact product and dispensing pharmacy?”
“What is included in the care price, and what is separate—medication, labs, shipping, follow-up, or video visits?”
“What is the full recurring cost over 365 days, and is billing every calendar month or every 28 days?”
“If I cancel, what happens to future refills, the prescription already written, and the payment already processed?”

Two of those questions come straight from live provider friction.

Winona’s 30-day supplies process every 28 days, and its full-refund window is tied to the first 24 hours after order processing. “Cancel anytime” does not mean “refund anytime.” Sesame’s monthly price excludes medication. Evernow’s membership and medication are separate. Midi’s commercial-insurance reach does not open the door for Medicaid or Medi-Cal.

Specific questions turn marketing language into terms you can actually compare.

Which state path is yours?

Answer capsule: Your best route depends on the collision between state, payer, medication, and visit preference. A mandate-state reader should check insurance before buying cash care. A Medicaid reader should not waste time on Midi. A testosterone reader needs a controlled-substance pathway. A cash-pay reader may value speed, but only after annualizing the complete cost.

Your situation	The move	Why
Illinois, Louisiana, Oregon, or an applicable New Jersey plan	Check the state benefit and an insurance-billing provider before cash care	The mandate may reduce the visit or medication cost, but only if your plan and service fall within it
Virginia plan beginning January 1, 2027	Ask how the new benefit applies at issue or renewal	The statute is enacted, but the policy applicability date has not arrived as of this verification
Commercial insurance, any state	Start with a provider that bills the plan and sends medication to the pharmacy benefit	This often produces the lowest full-year total
Medicaid or Medi-Cal	Skip Midi; check an in-network local clinician or Elektra only where the exact plan is listed	Beneficiary eligibility is a provider-level gate
Medicare	Compare a participating local clinician with Elektra’s state-and-plan-specific participation	Visit coverage and Part D drug coverage are separate
Cash-pay, age 35–59, in Winona’s footprint, and no live visit preferred	Consider Winona after confirming product, 28-day billing, and refund timing	The asynchronous path is the benefit; the narrower footprint and billing model are the tradeoff
A noncontrolled prescription sent to your pharmacy	Compare Wisp, Sesame, Midi, Gennev, or Elektra based on care model and payer	The local-pharmacy route keeps the medication price separate from the care fee
Testosterone matters	Check Midi’s 24-state-plus-D.C. list or Elektra’s New York-only statement; otherwise start in person	Controlled-substance access cannot be inferred from general HRT availability
Not sure which row is yours	Use Find My HRT Path	It routes by state, payer, medication lane, and when online care is not the right starting point

Decision Resolution Point — Winona’s exact fit: if you are 35–59, live in one of its listed jurisdictions, prefer no phone or video visit, and accept cash pricing plus the 28-day processing cycle, compare Winona’s terms with the strongest alternatives before you start.

How did we verify this page?

Answer capsule: We applied The HRT Index Verification Standard to geography: read current provider price and footprint pages, separate FDA-approved from compounded finished drugs, trace enacted laws to official sources, calculate recurring costs from published intervals, and label what remains provider-published rather than independently tested. No provider receives a numeric score, and no unsupported state inference is published.

The HRT Index Verification Standard examines providers through five pillars in this exact order: clinical legitimacy, care quality, medication fit, price transparency, access.

For this page:

Provider-published means the claim appeared on the company’s live page on September 2, 2026.
Official law read means we traced the reader-facing statement to an enacted statute, public act, or state regulator.
Calculated means we show the formula from published prices and billing intervals.
Not independently tested means we did not enroll, purchase, time response, or complete checkout in every state.

We re-check provider pricing, state directories, insurance statements, laboratory inclusion, cancellation terms, and testosterone jurisdictions monthly. We check state laws monthly during active legislative sessions and quarterly otherwise. Federal controlled-substance rules are re-checked on every DEA announcement.

Read the full methodology.

Found something out of date? Email partners@thehrtindex.com with the source and date. Corrections should be visible, dated, and proportional to what changed.

Frequently asked questions about HRT prescriptions by state

Is HRT legal in all 50 states?

Our September 2026 review found no state law banning FDA-approved menopausal hormone therapy for menopause. The prescription still must come from a clinician who can lawfully treat you and who decides the medication is appropriate.

Can an out-of-state clinician prescribe estrogen to me?

Yes, when the clinician is licensed or otherwise authorized where you are physically located during the telehealth encounter and the prescription complies with that jurisdiction’s rules. The clinician’s office address is not the deciding location.

Does my home address or current location matter?

Your physical location during the appointment generally controls telehealth licensure. Tell the provider if you are traveling; do not assume a home address preserves the appointment.

Why did an “all 50 states” provider reject me?

The company may lack clinician capacity, not offer the requested product in your state, be unable to use its pharmacy there, not accept your payer, need a different visit format, or refuse the request after clinical review.

Does “all 50 states” include Washington, D.C. or Puerto Rico?

No. They are separate jurisdictions. Evernow explicitly lists Washington, D.C.; Winona explicitly lists Puerto Rico. Ask every other provider rather than expanding a “50 states” claim yourself.

Which states require insurance to cover menopause treatment?

Illinois, Louisiana, New Jersey, Oregon, and Virginia have enacted menopause-treatment coverage mandates. Virginia applies to policies beginning January 1, 2027. Washington has a separate refill law, not a treatment-coverage mandate.

Does a mandate make treatment free?

No. Network rules, cost sharing, medical necessity, formulary restrictions, prior authorization, benefit design, and plan type can still matter. A self-funded employer plan may not be bound by the state mandate.

How do I know whether my employer plan is self-funded?

Ask HR or the plan administrator directly. Do not infer it from the insurance card because a carrier can administer both fully insured and self-funded plans.

Does Medicaid cover HRT?

Coverage and utilization rules vary by state. Louisiana and New Jersey enacted menopause benefits that include their Medicaid programs, but formulary, prior authorization, and provider participation still have to be checked.

Does Medicare cover online menopause care?

Medicare visit coverage, clinician participation, and Part D drug coverage are separate questions. Midi does not bill Medicare; Elektra lists selected Medicare participation in specified states. Confirm the exact plan and clinician before booking.

Do I need bloodwork before an online HRT prescription?

Not every menopause evaluation requires hormone testing, but the answer depends on symptoms, menstrual history, medication, and medical history. Testosterone pathways generally require baseline and follow-up laboratory monitoring. A state footprint does not decide the clinical need for labs.

Can a telehealth clinician prescribe vaginal estrogen?

A licensed clinician can prescribe FDA-approved local vaginal estrogen when clinically appropriate and legally authorized where the patient is located. Local vaginal treatment and systemic hormone therapy are different lanes and should not be presented as interchangeable.

Can a nurse practitioner prescribe HRT?

Often, but prescriptive authority and physician-collaboration requirements vary by state and profession. The provider still has to assign a clinician whose authority fits the patient’s location and medication.

Can telehealth prescribe testosterone to women?

Sometimes. The prescription is off-label for women, testosterone is Schedule III, and the provider must satisfy federal and state controlled-substance rules. Midi publishes 24 states plus D.C.; Elektra’s public statement is limited to some clinicians serving New York residents.

Can the provider send a prescription to my usual pharmacy?

Many visit-based services do, including Midi, Gennev, Wisp, Sesame, and Elektra. Bundled programs may use their own pharmacy. Confirm the exact product and fee before assuming an outside-pharmacy route.

What happens if I travel or move?

Tell the provider where you will physically be during the visit, ask whether the clinician can treat you there, and confirm pharmacy transfer or shipping before you leave. For a permanent move, establish the new prescriber before canceling the old service.

Are state HRT prescribing rates publicly available?

We did not find a current public all-payer dataset covering every state. National, Medicare, insurer, and health-system datasets answer narrower questions and should not be represented as a complete 50-state prescribing map.

Where you live changes how you get hormone therapy. It does not turn a provider’s missing license into a ban, a cash price into your only option, or a “50 states” badge into proof that every medication and payer will work.

Still not sure which HRT program is right for you? Take our free 60-second matching quiz: Find My HRT Path.

Sources

Federal, regulatory, and clinical

State law and insurance

Prescribing-trend data

Provider-published sources checked September 2, 2026

Choose the care route that matches your state and coverage.

Compare the best online HRT providers, review the HRT insurance coverage guide, or use Find My HRT Path to compare state, payer, medication, and care-model constraints.

Keep reading: